Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - Section for Cellular Therapy

8 publications found

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Caulier B, Enserink JM, Wälchli S (2021)
Pharmacologic Control of CAR T Cells
Int J Mol Sci, 22 (9)
DOI 10.3390/ijms22094320, PubMed 33919245

Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2021)
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
Oncoimmunology, 10 (1), 1936757
DOI 10.1080/2162402X.2021.1936757, PubMed 34235003

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
J Pers Med, 11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815

Heck A, Winge-Main AK (2021)
Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors
BMJ Case Rep, 14 (5)
DOI 10.1136/bcr-2021-241981, PubMed 34045201

Ito J, Minemura T, Wälchli S, Niimi T, Fujihara Y, Kuroda S, Takimoto K, Maturana AD (2021)
Id2 Represses Aldosterone-Stimulated Cardiac T-Type Calcium Channels Expression
Int J Mol Sci, 22 (7)
DOI 10.3390/ijms22073561, PubMed 33808082

Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, Wälchli S (2021)
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms
FASEB J, 35 (9), e21750
DOI 10.1096/fj.202100025R, PubMed 34424568

Vestre K, Persiconi I, Borg Distefano M, Mensali N, Guadagno NA, Bretou M, Wälchli S, Arnold-Schrauf C, Bakke O, Dalod M, Lennon-Dumenil AM, Progida C (2021)
Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton
J Cell Sci, 134 (18)
DOI 10.1242/jcs.259221, PubMed 34494097

 
Page visits: 647306